



Patent
Attorney's Docket No. 033352-010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Cruz, et al.) Group Art Unit: 1653
Application No.: 09/978,309) Examiner: Unassigned
Filed: October 15, 2001)
For: Compositions and Methods for Treating)
Cellular Response to Injury and Other)
Proliferating Cell Disorders Regulated by)
Hyaladherin and Hyaluronans)

SWL
12-15-03

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56,
Applicants hereby submit the following information in conformance with 37 C.F.R.
§§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited
below is enclosed.

- | | | | |
|-----|-----------|----------|------------------------|
| 1. | RE32,011 | 10/22/85 | Zimmerman et al. |
| 2. | 4,018,884 | 4/19/77 | Cleeland, Jr. et al. |
| 3. | 4,359,535 | 11/16/82 | Pieczenik |
| 4. | 4,376,110 | 3/8/83 | David et al. |
| 5. | 4,411,993 | 10/25/83 | Gillis |
| 6. | 4,486,530 | 12/4/84 | David et al. |
| 7. | 4,528,266 | 7/9/85 | Pieczenik |
| 8. | 4,543,439 | 9/24/85 | Frackelton, Jr. et al. |
| 9. | 4,551,433 | 11/5/85 | DeBoer |
| 10. | 4,603,112 | 7/29/86 | Paoletti et al. |
| 11. | 4,736,866 | 4/12/88 | Leder et al. |

TECH CENTER 1600/2900

FEB 26 2002

RECEIVED

| | | | |
|-----|-----------|----------|--------------------|
| 12. | 4,744,981 | 5/17/88 | Pavanasasivam |
| 13. | 4,745,051 | 5/17/88 | Smith et al. |
| 14. | 4,769,330 | 9/6/88 | Paoletti et al. |
| 15. | 4,816,567 | 3/28/89 | Snyder et al. |
| 16. | 4,851,341 | 7/25/89 | Hopp et al. |
| 17. | 4,870,009 | 9/26/89 | Evans et al. |
| 18. | 4,873,191 | 10/10/89 | Wagner et al. |
| 19. | 4,897,255 | 1/30/90 | Fritzberg et al. |
| 20. | 4,902,614 | 2/20/90 | Wakabayashi et al. |
| 21. | 4,987,071 | 1/22/91 | Cech et al. |
| 22. | 4,988,496 | 1/29/91 | Srinivasan et al. |
| 23. | 5,017,487 | 5/21/91 | Stunnenberg et al. |
| 24. | 5,087,571 | 2/11/92 | Leder et al. |
| 25. | 5,091,309 | 2/25/92 | Schlesinger et al. |
| 26. | 5,106,951 | 4/21/92 | Morgan, Jr. et al. |
| 27. | 5,110,833 | 5/5/92 | Mosbach |
| 28. | 5,166,057 | 11/24/92 | Palese et al. |
| 29. | 5,162,215 | 11/10/92 | Bosselman et al. |
| 30. | 5,169,784 | 12/8/92 | Summers et al. |
| 31. | 5,175,383 | 12/29/92 | Leder et al. |
| 32. | 5,175,384 | 12/29/92 | Krimpenfort et al. |
| 33. | 5,204,244 | 4/20/93 | Fell et al. |
| 34. | 5,217,879 | 6/8/93 | Huang et al. |
| 35. | 5,219,740 | 6/15/93 | Miller et al. |
| 36. | 5,221,778 | 6/22/93 | Byrne et al. |
| 37. | 5,225,539 | 7/6/93 | Winter |
| 38. | 5,242,687 | 9/7/93 | Fernandez-Pol |
| 39. | 5,243,041 | 9/7/93 | Tykocinski et al. |
| 40. | 5,254,678 | 10/19/93 | Haseloff et al. |

swl
12-15-03

| | | | |
|-----|-----------|----------|----------------------|
| 41. | 5,266,317 | 11/30/93 | Tomalski et al. |
| 42. | 5,288,514 | 2/22/94 | Ellman |
| 43. | 5,288,641 | 2/22/94 | Roizman |
| 44. | 5,328,834 | 7/12/94 | Ngo et al. |
| 45. | 5,359,051 | 10/25/94 | Cook et al. |
| 46. | 5,387,742 | 2/7/95 | Cordell |
| 47. | 5,347,075 | 9/13/94 | Sorge |
| 48. | 5,395,750 | 3/7/95 | Dillon et al. |
| 49. | 5,463,564 | 10/31/95 | Agrafiotis et al. |
| 50. | 5,482,856 | 1/9/96 | Fell, Jr. et al. |
| 51. | 5,506,337 | 4/9/96 | Summerton et al. |
| 52. | 5,545,808 | 8/13/96 | Hew et al. |
| 53. | 5,567,607 | 10/22/96 | Zhao et al. |
| 54. | 5,580,859 | 12/3/96 | Felgner et al. |
| 55. | 5,591,624 | 1/7/97 | Barber et al. |
| 56. | 5,633,076 | 5/27/97 | DeBoer et al. |
| 57. | 5,693,761 | 12/2/97 | Queen et al. |
| 58. | 5,693,762 | 12/2/97 | Queen et al. |
| 59. | 5,698,435 | 12/16/97 | Robinson et al. |
| 60. | 5,716,613 | 2/10/98 | Guber et al. |
| 61. | 5,716,826 | 2/10/98 | Gruber et al. |
| 62. | 5,716,832 | 2/10/98 | Barber et al. |
| 63. | 5,741,957 | 4/21/98 | Deboer et al. |
| 64. | 5,770,380 | 6/23/98 | Hamilton et al. |
| 65. | 5,780,009 | 7/14/98 | Karatzas et al. |
| 66. | 5,780,225 | 7/14/98 | Karatzas et al. |
| 67. | 5,789,245 | 8/4/98 | Dubensky, Jr. et al. |
| 68. | 5,814,482 | 9/29/98 | Dubensky, Jr. et al. |
| 69. | 5,817,491 | 10/6/98 | Yee et al. |

SWL
12-15-03

| | | | |
|-----|-----------------|----------|----------------------|
| 70. | 5,843,723 | 12/1/98 | Dubensky, Jr. et al. |
| 71. | 5,851,529 | 12/22/98 | Guber et al. |
| 72. | 5,840,479 | 11/24/98 | Little et al. |
| 73. | 5,849,288 | 12/15/98 | Reisner |
| 74. | 5,872,005 | 2/16/99 | Wang et al. |
| 75. | EP 0360 257 | 11/13/96 | |
| 76. | EP 0415 731 | 3/6/91 | |
| 77. | EP 044 0219 | 8/7/91 | |
| 78. | EP 0612844 (A2) | 8/31/94 | |
| 79. | WO 89/01973 | 3/9/89 | |
| 80. | WO 90/02809 | 3/22/90 | |
| 81. | WO 90/07862 | 7/26/90 | |
| 82. | WO 90/07936 | 7/26/90 | |
| 83. | WO 91/00285 | 1/10/91 | |
| 84. | WO 92/06693 | 4/30/94 | |
| 85. | WO 92/15677 | 9/17/92 | |
| 86. | WO 92/15679 | 9/17/92 | |
| 87. | WO 93/10218 | 5/27/93 | |
| 88. | WO 93/11230 | 6/10/93 | |
| 89. | WO 93/12227 | 6/24/93 | |
| 90. | WO 93/20242 | 10/14/93 | |
| 91. | WO 93/25234 | 12/23/93 | |
| 92. | WO 93/25698 | 12/23/93 | |
| 93. | WO 94/03622 | 2/17/94 | |
| 94. | WO 95/02566 | 1/26/95 | |
| 95. | WO 95/04277 | 2/9/95 | |
| 96. | WO 95/10607 | 4/20/95 | |
| 97. | WO 95/12387 | 5/11/95 | |
| 98. | WO 95/16209 | 6/15/95 | |

SW ✓
12-15-03

99. WO 95/16712 6/22/95
100. WO 95/16918 6/22/95
101. WO 95/24186 9/14/95
102. WO 95/24929 9/21/95
103. WO 95/30642 11/16/95
104. WO 96/00148 1/4/96
105. WO 97/38098 10/16/97
106. WO 99/01164 1/14/99:
107. Bauer, et al., "A genetic enrichment for mutations constructed by oligodeoxynucleotide-directed mutagenesis", *Gene*, 37:73-81, (1985).
108. Bird, et al., "Single-chain antigen-binding proteins", *Science*, 242:423-426, (1988).
109. Brinster, et al., "Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs", *Proc. Natl. Acad. Sci. U.S.A.*, 82:4438-4442, (1985).
110. Chothia, et al., "Domain association in immunoglobulin molecules", *J. Mol. Biol.*, 186:651, (1985).
111. Craik, et al., "Use of Oligonucleotides for site-specific mutagenesis", *BioTechniques*, pp. 12-19, (Jan. 1985).
112. Curiel, et al., "High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes", *Hum. Gene Ther.*, 3:147-154, (1992).
113. Drinkwater, et al., "Chemically induced mutagenesis in a shuttle vector with a low-background mutant frequency", *PNAS*, 83:3402-3406, (1986).
114. Fisher-Hoch, et al., "Protection of rhesus monkeys from fata Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene", *PNAS*, 86:317-321, (1989).
115. Flexner, et al., "Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2", *Vaccine*, 8:17-21, (1990).
116. Flexner, et al., "Vaccinia virus expression vectors", *Ann. N.Y. Acad. Sci.*, 569:86-103, (1989).
117. Forster, et al., "Self-cleavage of plus and minus RNAs of virusoid and a structural model for the active sites", *Cell*, 48:211-220, (1987).

See 2
12-15-03

118. Hammer, et al., "Production of transgenic rabbits, sheep and pigs by microinjection", *Nature*, 315:680-683, (1985).
119. Haseloff, J., et al., "Simple RNA enzymes with new and highly specific endoribonuclease activities", *Nature*, 334:585-591, (1988).
120. Hirashima, et al., "A new immune system against viral infection using antisense RNA: micRNA-immune system", *Molecular Biology of RNA: New Perspectives*, Academic Press, San Diego, CA, pp. 401-412, (1987).
121. Hopp, et al., "A short polypeptide marker sequence useful for recombinant protein identification and purification", *Bio/Technology*, 6:1204-1210, (1988).
122. Horwitz, et al., "Selection of new biological activities from random nucleotide sequences: evolutionary and practical considerations", *Genome*, 3:112-117, (1989).
123. Huse, et al., "Generation of large combinatorial library of the immunoglobulin repertoire in phage lambda", *Science*, 246:1275-1281, (1989).
124. Inman, J., "Covalent linkage of functional groups, ligands, and proteins to polyacrylamide beads", *Methods In Enzymology*, Vol. 34, *Affinity techniques, Enzyme Purification: Part B*, pp. 31-59, Jakoby and Wilcheck (eds.), Academic Press, New York, (1974).
125. Jones, et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse", *Nature*, 321:522-525, (1986).
126. Kit, *Adv. Exp. Med. Biol.*, 215:219-236 (1989).
127. Kohler, et al., "Continuous cultures of fused cells secreting antibody of predefined specificity", *Nature*, 256:495-497, (1975).
128. Kyte, et al., "A simple method for displaying the hydropathic character of a protein", *J. Mol., Biol.*, 157:105-132, (1982).
129. Liao, et al., "A simple high-efficiency method for random mutagenesis of cloned genes using forced nucleotide misincorporation", *Gene*, 88:107-111, (1990).
130. Look, et al., "The Identification of Cyclooxygenase-1 Inhibitors from 4-Thiazolidinone Combinatorial Libraries," *Bioorg and Med. Chem. Letters*, 6:707-712, (1996).
131. Luytjes, et al., "Amplification, express, and packaging of a foreign gene by influenza virus", *Cell*, 59:1107-1113, (1989).

601
12-15-03

132. Mastronardi, et al., "Demyelination in a transgenic mouse: a model for multiple sclerosis", *J. Neurosci. Res.*, (93), Vol. 36, pp. 315-324.
133. Morrison, et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains", *Proc. Natl. Acad. Sci. U.S.A.*, 81:6851-6855, (1984).
134. McMichael, et al., "Cytotoxic t-cell immunity to influenza", *N. Eng. J. Med.*, 309: 13-17, (1983).
135. Mulligan, et al., "Synthesis of rabbit- β -globin in cultured monkey kidney cells following infection with a SV40 β -globin recombinant genome", *Nature*, 277:108-114, (1979).
136. Novotny et al., "Structural invariants of antigen binding: comparison of immunoglobulin VL-VH and VL-VL domain dimers" *Proc. Natl. Acad. Sci. U.S.A.*, 82:4592-4596, (1985).
137. Palmiter, et al., "Metallothionein-human GH fusion genes stimulate growth of mice", *Science*, 222:809-814, (1983).
138. Palmiter, et al., "Transgenic mice", *Cell*, 41:343-345, (1985).
139. Phillips, et al., "Solid-phase Synthesis of Benzimidazoles," *Tet. Letters*, 37:4887-4890, (1996).
140. Poznansky, "Gene transfer into human lymphocytes by a defective human immunodeficiency virus type-1 vector", *J. Virol.*, 65:532-536, (1991).
141. Presta, L., "Antibody engineering", *Curr. Op. Struct., Biol.*, 2:593-596, (1992).
142. Reichmann, et al., "Reshaping human antibodies for therapy", *Nature*, 332:323-327 (1988).
143. Ruhland, et al., "Solid-supported Combinatorial Synthesis of Structurally Diverse Beta-Lactams", *J. Amer. Chem. Soc.*, 111:253-254, (1996).
144. Sastry, et al., "Cloning of immunological repertoire in *Escherichia coli* for generation of monoclonal catalytic antibodies: construction of a heavy chain variable region-specific cDNA library:", *Proc. Natl. Acad. Sci. U.S.A.*, 86:5728-5732, (1989).
145. Scatchard, G., "The attractions of proteins for small molecules and ions", *Ann. N.Y. Acad. Scien.*, 51:660-672, (1949).

swl
12-15-03

146. Stein, et al., "Antisense oligonucleotides as therapeutic agents-is the bullet really magical?", *Science*, 261:1004-1012, (1993).
147. Uhlenbeck, O., "A small catalytic oligoribonucleotide", *Nature*, 328:596-600, (1988).
148. von Heijne, "Signal sequences: the limits of variation", *J. Mol. Biol.*, 184:99-105, (1985).
149. Walbot, et al., "Plant development and ribozymes for pathogens", *Nature*, 334:196-197, (1988).
150. Walder, et al., "Oligodeoxynucleotide-directed mutagenesis using the yeast transformation system", *Gene*, 42:133-139, (1986).
151. Wang, et al., "The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression", *Clinical Cancer Research*, 4:567-576, (1998).
152. Wilchek, et al., "The Avidin-Biotin Complex in Bioanalytical Applications", *Anal. Biochem.*, 171:1-32, (1988).
153. Wu, et al., "Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements *in vivo*", *J. of Biol. Chem*, 264:16985-16987, (1989).
154. Yap, et al., *Nature*, 273:238-239, (1978).
155. Zaho, et al., "Influence of ⁷Li on disease progression in murine models of diabetes: differences between NOD and obese mice", *Lithium*, 2(4), pp. 227-234, (1991).

swl
12-15-03